Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in ...

After approval in late 2024, Johnson & Johnson's Varipulse PFA system started 2025 on the wrong foot: Its early rollout had ...

In January 2025, we reported that some adverse events associated with gabapentin (Neurontin) may have been overestimated.

SENA Health addresses these challenges by transforming patient access, engagement, and care coordination through its AI-powered Command Center. The platform is designed to supplement, or fully replace ...

More and more of us rating our fitness as ‘excellent' but, according to an annual health tracker, there are still too many ...

Contemporary cardiology faces a paradox: unprecedented technological capability coincides with declining scientific curiosity ...

Biohacks and understanding what makes your brain and body perform at their optimum are the foundations for long-term performance.

From the quick arrival of paramedics to the foresight of physicians, it was modern medicine that saved John Griffith’s life ...

Live Science spoke with Dr. Joe Alexander of NTT Research about "digital twins" and the development of an autonomous device ...

Obesity and diabetes treatment is undergoing a revolution with the advent of GLP-1 drugs, which help manage weight, control ...